ArticleAfrican health sciences2020
Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia.
Article in African health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.International journal of molecular sciences · 2026Review
- Regulatory B cells andBiomolecules & biomedicine · 2026Article
- Regulatory B Cells at the Crossroads of Epigenetic Control and Immune Homeostasis.Clinical reviews in allergy & immunology · 2026Review
- Cytokines IL-6, IL-10, and CCL5 Secreted by Infiltrating B Cells Promote Cell Migration of Human Prostate Cancer Cell Lines.Oncology research · 2026Article
- The immune landscape of systemic inflammation in prostate cancer.Cancer biology & medicine · 2025Review
- Analysis of IL10 gene promoter haplotypes and changes in mRNA expression and soluble levels in patients with basal cell carcinoma.Archives of dermatological research · 2025Article
- Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis.Frontiers in immunology · 2025Review
- Endothelial cells in tumor microenvironment: insights and perspectives.Frontiers in immunology · 2024Review
- Inflammation in Prostate Cancer: Exploring the Promising Role of Phenolic Compounds as an Innovative Therapeutic Approach.Biomedicines · 2023Review
- Effect of IL-10-producing B cells in peripheral blood and tumor tissue on gastric cancer.Cell communication and signaling : CCS · 2023Article
- Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?Biomarker research · 2023Review
- Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy.Biomarker research · 2023Review
- Article
- Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer.Frontiers in immunology · 2023Review
- B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.Nature reviews. Clinical oncology · 2022Review
- B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication.Frontiers in cell and developmental biology · 2021Review
- A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy.Frontiers in oncology · 2021Review
- Twenty years ofAfrican health sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe function of the immune system in prostate cancer (PC) might promote carcinogenesis. PC is a common cancer in men. Regulatory B cells (Bregs) are a new subtype of B cells that have suppressive roles in the immune system. Interleukin-10 (IL-10) is a dominant mediator of immune suppression released by Bregs.
objectiveThe purpose of this research was to examine the frequency of CD19+IL10+ B cells and IL-10 mRNA expression in patients with PC compared to patients with benign prostatic hyperplasia (BPH).
methodsForty paraffin tissue samples from patients with PC and 32 paraffin tissue samples from patients with BPH were entered in this study. The immunohistochemistry staining was used to evaluate the pattern expression of CD19 and IL-10 markers. IL-10 mRNA expression in fresh tissue was determined by real time-polymerase chain reaction (RT-PCR).
resultsThe frequency of CD19+IL-10+ B cells and IL-10 mRNA expression in PC patients were significantly higher than patients with BPH. Also, there was no meaningful relationship between the frequency of IL-10+CD19+ B cells and gleason scores in patients with PC.
conclusionsOur findings suggested that frequency of IL-10+CD19+ B cells correlates with progressive stage of PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.